Aldeyra Therapeutics (ALDX) Assets Average (2014 - 2026)

Aldeyra Therapeutics (ALDX) has reported Assets Average for 13 consecutive years, with $57.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets Average fell 36.0% year-over-year to $57.0 million; the trailing twelve-month figure through Jun 2026 stood at $57.0 million (down 36.0% YoY), and the FY2025 full-year result was $88.3 million, down 30.15% from the prior year.
• Assets Average fell to $57.0 million in Q2 2026 per ALDX's latest filing, from $69.3 million in the prior quarter.
• Across five years, Assets Average topped out at $227.9 million in Q1 2022 and bottomed at $57.0 million in Q2 2026.
• Historically, Assets Average has averaged $135.5 million across 5 years, with a median of $139.2 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Assets Average surged 97.62% in 2022, then tumbled 36.0% in 2026.
• Over 5 years, Assets Average stood at $185.5 million in 2022, then dropped by 20.32% to $147.8 million in 2023, then declined by 24.93% to $111.0 million in 2024, then slumped by 32.47% to $74.9 million in 2025, then retreated by 23.91% to $57.0 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $57.0 million, $69.3 million, and $74.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.